Bold Move To Embed Biosimilar Switching Aims To Bring Savings Of Up To £300m For NHS England
NHS England has produced a new framework intended to increase the use of biosimilars and generate savings of £200-300m on the drugs bill each year by 2020/21. An initial focus will be AbbVie’s Humira (adalimumab) and Roche’s Herceptin (trastuzumab), which are due to face biosimilar competition in the UK soon. Biosimilars firms have welcomed the move, but the R&D-based industry believes the savings targets set out in the document are unrealistic.
You may also be interested in...
Biogen: Patients Must Be At Center Of UK Biosimilar Decision Making
The head of biosimilars for Biogen in the UK & Ireland, Jim Porter, sat down with Generics Bulletin to discuss “system challenges and changes that we’re seeing within the UK’s NHS,” as well as Biogen’s own position in what it says is a very important market for the company.
Biosimilar Confidence And Knowledge Needed In Europe, Say Experts
European biosimilar market penetration varies widely across the EU member states and disease groups, with different government policies on promotion, purchasing and communication leading to mistrust. The European Commission is looking to boost confidence in biosimilars to support their uptake on a much wider scale across Europe, and to get a bird's eye view of what is driving or hindering the EU market for biosimilars.
European Parliament Wants EU-Wide Pull Incentive Scheme For New Antimicrobials
The three major EU institutions are all calling for urgent action to tackle antimicrobial resistance, with the emphasis very much on incentives for the development of novel medicines and a reduction in overall consumption of antibiotics.